{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:10:30Z","timestamp":1789729830633,"version":"4.0.1"},"reference-count":0,"publisher":"California Digital Library (CDL)","issue":"3","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Practice and Cases in Emergency Medicine"],"abstract":"<p>Introduction: Brugada syndrome, a cardiac channelopathy, manifests with ventricular arrhythmia. Diagnosis relies on a type 1 Brugada electrocardiogram (ECG) pattern, while type 2 and type 3 patterns may necessitate electrophysiologic testing to uncover an underlying type 1 Brugada pattern. Differentiation between these patterns is important, as type 1 patterns pose a significantly greater risk of arrhythmia relative to types 2 and 3 counterparts. Case Report: A 14-year-old male with autism presented after a syncopal episode following a lurasidone dosage increase. His ECG revealed a type 2 Brugada pattern. He was monitoredovernight in the pediatric intensive care unit, where he remained asymptomatic. After being discharged with a Holter monitor, a quaternary hospital\u2019s procainamide challenge test weeks later contradicted an official diagnosis of Brugada syndrome, as dictated by elucidation of a type 1 Brugada pattern. After reverting to the initial lurasidone dose, a follow-up ECG after two months showed no Brugada pattern. Conclusion: In syncope cases, an ECG is crucial for identifying arrhythmogenic causes, including Brugada syndrome. This case highlights an ECG suggestive of Brugada syndrome with negative pharmacological tests and resolution post-discontinuation of the offending agent. Emergency physicians should be vigilant for Brugada and long QT syndromes in patients on antipsychotic medications.<\/p>","DOI":"10.5811\/cpcem.1573","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T14:13:20Z","timestamp":1748441600000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case Report: Lurasidone-Induced Type 2 Brugada Pattern in a Pediatric Patient"],"prefix":"10.5811","volume":"9","author":[{"given":"Ethan","family":"Start","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Aldrin Guevarra","family":"Enabore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"29705","published-online":{"date-parts":[[2025,5,28]]},"container-title":["Clinical Practice and Cases in Emergency Medicine"],"original-title":[],"link":[{"URL":"https:\/\/escholarship.org\/content\/qt1mz6g9hb\/qt1mz6g9hb.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:18:25Z","timestamp":1753863505000},"score":1,"resource":{"primary":{"URL":"https:\/\/escholarship.org\/uc\/item\/1mz6g9hb"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,30]]}},"URL":"https:\/\/doi.org\/10.5811\/cpcem.1573","relation":{},"ISSN":["2474-252X"],"issn-type":[{"value":"2474-252X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}